Lung Cancer Vaccines
Creative Biolabs is a world leader in the field of cancer vaccine development. With our extensive experience and advanced platform, we are therefore confident in offering the best services for vaccine development against lung cancer and guarantee the finest results for our customers all over the world.
Lung Cancer
Lung cancer is by far the deadliest type of cancer in the United States and worldwide. The two major forms of lung cancer are non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLC comprises about 85% of all lung cancers, and nearly all the cases are one of three major histologies: adenocarcinoma, squamous-cell carcinoma, and large-cell carcinoma. However, for most recent clinical trials, NSCLC has been divided into squamous and nonsquamous NSCLC. A great majority of nonsquamous disease is adenocarcinoma. Adenocarcinoma and squamouscell carcinoma have a similar etiology (generally cigarette smoking) and similar mutational load. However, there is a subset of NSCLC, usually adenocarcinoma, that is generally found in nonsmokers and is associated with specific genomic abnormalities, such as mutations in epidermal growth factor (EGF) receptor (EGFR) or rearrangements involving the anaplastic lymphoma kinase (ALK). Tumors from these patients generally have fewer mutations and are often clinically treated quite differently. SCLC comprises approximately 15% of the patients with lung cancer and it is almost always related to smoking. However, mutational load in SCLC is relatively low as compared to NSCLC. Although important new findings in the treatment of advanced NSCLC have led to significant progress, improvements have been incremental.
Therapeutic Vaccines for Lung Cancer
As a result of published literature showing a potential role for immunotherapy in lung cancer, and data demonstrating a cytolytic T cell response to tumor antigens by TIL in lung adenocarcinoma, active immunotherapy strategies such as cancer vaccines were investigated in an attempt to elicit antigen-specific immune responses. Several vaccines have been developed to target shared or tumor-specific antigens in lung cancer.
Our Lung Cancer Vaccine Platforms
Antigen-Specific Vaccines
- MUC-1: MUC-1 is a transmembrane glycoprotein expressed on normal epithelia as well as by tumor cells (TCs) from a variety of malignancies, including NSCLC. Studies suggest that this protein plays a role in the growth and survival of tumors and is associated with disease progression and worse prognosis in lung cancer. The MUC-1 peptide is highly immunogenic and has been shown to elicit a strong T cell response in animal models and patients;
- Melanoma antigen encoding gene A3: The melanoma antigen genes A, B, and C are a family of genes that are normally silenced except during embryogenesis and in male germ cells. The members of this gene family are considered TAAs because they are aberrantly expressed in several different tumors, including lung cancers, and thus represent a potential target for cancer immunotherapy. Melanoma-associated antigen-3 (MAGE-3) is a subtype of the MAGE gene family that is expressed in 55% of advanced-stage NSCLC, with higher levels of expression associated with poor prognosis;
- Other antigen-specific vaccines.
Non-Antigen-Specific Vaccines
Creative Biolabs is a leader in the field of vaccine development and has focused on the cancer vaccines for years. We have experts who are able to help you with the development of the lung cancer vaccines. If you are interested in our services, please contact us for more details.
All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.
